Market Overview:
The global pet biopharmaceuticals market is expected to register a CAGR of 7.8% during the forecast period, 2018-2030. The growth in this market can be attributed to the increasing prevalence of zoonotic diseases, rising demand for companion animals, and technological advancements in the field of pet biopharmaceuticals. Based on type, the global pet biopharmaceuticals market is segmented into antiparasitic products, biological products, antibacterial products and others. Antiparasitic products are further sub-segmented into parasiticides for dogs and parasiticides for cats. Biological products are further sub-segmented into vaccines and therapeutics. Vaccines are further sub-segmented into core vaccines and combination vaccines while therapeutics are further sub-segmented into antihelminthics drugs (ivermectin) and anthelmintic drugs (praziquantel). Based on application, the global pet biopharmaceuticals market is segmented into prevention and treatment applications. Prevention applications include prophylactic vaccination against infectious diseases while treatment applications include therapeutic intervention against infections caused by parasites or bacteria in pets such as dogs or cats respectively . Regionally speaking North America dominates the global Pet Biopharma Market with a share of more than 30%.
Product Definition:
A pet biopharmaceutical is a pharmaceutical product that is derived from or inspired by a living organism. These products can be used to treat and prevent diseases in animals. The use of pet biopharmaceuticals can improve the quality of life for animals, and help to reduce the cost of veterinary care.
Antiparasitic:
Antiparasitic is a drug used to treat parasitic infections. It works by killing the parasites that are causing the infection. The most common type of parasitic infection is malaria, which affects red blood cells and causes anemia. Malaria can be treated with various drugs, some of which may damage kidney or liver function in the process.
Biological Products:
Biological products are living organisms and their derivatives, such as vaccines, blood transfusions, tissue & cell culture. Biological products have been used in the development of biopharmaceuticals for several years. The process involves extraction of active ingredients from biological sources using biotechnology techniques.
The global market is expected to grow at a lucrative rate during the forecast period owing to factors such as increasing R&D activities by major players.
Application Insights:
The prevention segment dominated the global pet biopharmaceuticals market in 2017. This can be attributed to the rising prevalence of chronic diseases, such as cancer and cardiac disorders in companion animals. According to a study published by the American Pet Products Association (APPA), it was estimated that around 54% of cats and 56% of dogs in U.S., are suffering from some form of chronic disease or disorder.
In addition, there is an increasing demand for preventative healthcare measures for pets due to rising awareness among pet owners regarding preventive care benefits and cost-effectiveness associated with them over alternative methods such as surgery or medication therapy options.
Regional Analysis:
North America dominated the global market in 2017. The growth is majorly attributed to the presence of a strong base of pet population, increasing R&D investments by companies for development of novel therapies for pets and rising pet owners’ willingness to spend on their four-legged friends. Moreover, high adoption rate and favorable government initiatives are expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to factors such as growing economy, improving healthcare infrastructure along with rising disposable income especially in emerging countries such as China and India which has led an increase in animal ownership thus fueling demand for biopharmaceuticals products over this region. Furthermore, Japan has one of the highest dog ownership rates globally; hence boosting product sales across this region significantly.
Growth Factors:
- Increasing demand for companion animals
- Rising awareness about animal health and well-being
- Growing number of veterinary clinics and hospitals
- Proliferation of pet biotechnology companies
- Advances in pet therapeutics
Scope Of The Report
Report Attributes
Report Details
Report Title
Pet Biopharmaceuticals Market Research Report
By Type
Antiparasitic, Biological Products, Antibacterial, Others
By Application
Prevention, Treatment
By Companies
Zoetis, Boehringer Ingelheim, Merck, Elanco, Virbac, Dechra Veterinary Products, Ceva, Vetoquinol, Ouro Fino Saude, Norbrook, Jindun, Chopperlvya Animal Health, CAHIC
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
207
Number of Tables & Figures
145
Customization Available
Yes, the report can be customized as per your need.
Global Pet Biopharmaceuticals Market Report Segments:
The global Pet Biopharmaceuticals market is segmented on the basis of:
Types
Antiparasitic, Biological Products, Antibacterial, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Prevention, Treatment
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Zoetis
- Boehringer Ingelheim
- Merck
- Elanco
- Virbac
- Dechra Veterinary Products
- Ceva
- Vetoquinol
- Ouro Fino Saude
- Norbrook
- Jindun
- Chopperlvya Animal Health
- CAHIC
Highlights of The Pet Biopharmaceuticals Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antiparasitic
- Biological Products
- Antibacterial
- Others
- By Application:
- Prevention
- Treatment
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pet Biopharmaceuticals Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pet biopharmaceuticals are medications specifically designed to treat diseases or conditions in pets. These medications can be administered through food, water, or injection.
Some of the major companies in the pet biopharmaceuticals market are Zoetis, Boehringer Ingelheim, Merck, Elanco, Virbac, Dechra Veterinary Products, Ceva, Vetoquinol, Ouro Fino Saude, Norbrook, Jindun, Chopperlvya Animal Health, CAHIC.
The pet biopharmaceuticals market is expected to grow at a compound annual growth rate of 7.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Pet Biopharmaceuticals Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Pet Biopharmaceuticals Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Pet Biopharmaceuticals Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Pet Biopharmaceuticals Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Pet Biopharmaceuticals Market Size & Forecast, 2018-2028
4.5.1 Pet Biopharmaceuticals Market Size and Y-o-Y Growth
4.5.2 Pet Biopharmaceuticals Market Absolute $ Opportunity
Chapter 5 Global Pet Biopharmaceuticals Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Pet Biopharmaceuticals Market Size Forecast by Type
5.2.1 Antiparasitic
5.2.2 Biological Products
5.2.3 Antibacterial
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Pet Biopharmaceuticals Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Pet Biopharmaceuticals Market Size Forecast by Applications
6.2.1 Prevention
6.2.2 Treatment
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Pet Biopharmaceuticals Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Pet Biopharmaceuticals Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Pet Biopharmaceuticals Analysis and Forecast
9.1 Introduction
9.2 North America Pet Biopharmaceuticals Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Pet Biopharmaceuticals Market Size Forecast by Type
9.6.1 Antiparasitic
9.6.2 Biological Products
9.6.3 Antibacterial
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Pet Biopharmaceuticals Market Size Forecast by Applications
9.10.1 Prevention
9.10.2 Treatment
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Pet Biopharmaceuticals Analysis and Forecast
10.1 Introduction
10.2 Europe Pet Biopharmaceuticals Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Pet Biopharmaceuticals Market Size Forecast by Type
10.6.1 Antiparasitic
10.6.2 Biological Products
10.6.3 Antibacterial
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Pet Biopharmaceuticals Market Size Forecast by Applications
10.10.1 Prevention
10.10.2 Treatment
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Pet Biopharmaceuticals Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Pet Biopharmaceuticals Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Pet Biopharmaceuticals Market Size Forecast by Type
11.6.1 Antiparasitic
11.6.2 Biological Products
11.6.3 Antibacterial
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Pet Biopharmaceuticals Market Size Forecast by Applications
11.10.1 Prevention
11.10.2 Treatment
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Pet Biopharmaceuticals Analysis and Forecast
12.1 Introduction
12.2 Latin America Pet Biopharmaceuticals Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Pet Biopharmaceuticals Market Size Forecast by Type
12.6.1 Antiparasitic
12.6.2 Biological Products
12.6.3 Antibacterial
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Pet Biopharmaceuticals Market Size Forecast by Applications
12.10.1 Prevention
12.10.2 Treatment
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Pet Biopharmaceuticals Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Pet Biopharmaceuticals Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Pet Biopharmaceuticals Market Size Forecast by Type
13.6.1 Antiparasitic
13.6.2 Biological Products
13.6.3 Antibacterial
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Pet Biopharmaceuticals Market Size Forecast by Applications
13.10.1 Prevention
13.10.2 Treatment
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Pet Biopharmaceuticals Market: Competitive Dashboard
14.2 Global Pet Biopharmaceuticals Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Zoetis
14.3.2 Boehringer Ingelheim
14.3.3 Merck
14.3.4 Elanco
14.3.5 Virbac
14.3.6 Dechra Veterinary Products
14.3.7 Ceva
14.3.8 Vetoquinol
14.3.9 Ouro Fino Saude
14.3.10 Norbrook
14.3.11 Jindun
14.3.12 Chopperlvya Animal Health
14.3.13 CAHIC
